title: Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells.
abstract: Although diagnosis and treatment of gastric cancer have improved, the prognosis of patients remains poor. The majority of patients should be treated with chemotherapy or other follow-up treatment. However, the drug resistance of chemotherapy and heterogeneity of tumor itself lead to differences of sensitivity of chemotherapy drugs for different patients. Therefore, it is mandatory to develop better methods of treatment for treatment of gastric cancer. Calycosin has been used in several types of cancer cells. Cisplatin, 5-fluorouracil (5-FU), and adriamycin (ADM) are most widely used drugs for chemotherapy, and they improve the overall survival of cancer patients. To study whether and how calycosin enhances their inhibition of gastric cancer cells, we detected the signaling pathway in which calycosin and cisplatin, 5-FU, and ADM play role in human gastric cells lines. We found that calycosin can enhance the suppression of cisplatin to gastric cell line by inhibiting the phosphorylation of protein kinase B (Akt). So, when cisplatin/5-FU/ADM is combined with calycosin, it can achieve better therapeutic effect in lower concentration.
authors.affiliation: a Third Affiliated Hospital , Liaoning Medical College , Jinzhou , China.
authors.forename: Lixia
authors.initials: L
authors.lastname: Zhou
authors.affiliation: a Third Affiliated Hospital , Liaoning Medical College , Jinzhou , China.
authors.forename: Yueming
authors.initials: Y
authors.lastname: Wu
authors.affiliation: b First Affiliated Hospital , Jinzhou Medical University , Fuzhou , China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Guo
authors.affiliation: a Third Affiliated Hospital , Liaoning Medical College , Jinzhou , China.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Li
authors.affiliation: a Third Affiliated Hospital , Liaoning Medical College , Jinzhou , China.
authors.forename: Na
authors.initials: N
authors.lastname: Li
authors.affiliation: a Third Affiliated Hospital , Liaoning Medical College , Jinzhou , China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Yang
authors.affiliation: a Third Affiliated Hospital , Liaoning Medical College , Jinzhou , China.
authors.forename: Xueyun
authors.initials: X
authors.lastname: Qin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D004789:Enzyme Activation; D005472:Fluorouracil / Q000494:pharmacology*; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology*; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000378:metabolism; D034622:RNA Interference; D015398:Signal Transduction / Q000187:drug effects*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D013997:Time Factors; D014162:Transfection
chemical_list: D051017:Apoptosis Regulatory Proteins; D018797:Cell Cycle Proteins; D007529:Isoflavones; D047428:Protein Kinase Inhibitors; C121707:7,3'-dihydroxy-4'-methoxyisoflavone; D004317:Doxorubicin; D051057:Proto-Oncogene Proteins c-akt; D002945:Cisplatin; D005472:Fluorouracil
keywords: 5-FU; ADM; Akt; Calycosin; cisplatin; gastric cell